BofA Securities upgraded Teladoc from Neutral to Buy and set a new price target of $7.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2026 | $7.00 | Neutral → Buy | BofA Securities |
| 12/9/2025 | $8.50 | Equal Weight | Barclays |
| 11/13/2025 | $8.00 | Market Perform | BMO Capital Markets |
| 7/25/2025 | $10.00 | Neutral | Mizuho |
| 11/15/2024 | $14.00 | Buy | Goldman |
| 9/17/2024 | $8.00 → $10.00 | Hold | Jefferies |
| 2/29/2024 | $22.00 | Overweight | Cantor Fitzgerald |
| 2/26/2024 | $17.00 | Market Perform | Leerink Partners |
BofA Securities upgraded Teladoc from Neutral to Buy and set a new price target of $7.00
Barclays initiated coverage of Teladoc with a rating of Equal Weight and set a new price target of $8.50
BMO Capital Markets initiated coverage of Teladoc with a rating of Market Perform and set a new price target of $8.00
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
S-8 - Teladoc Health, Inc. (0001477449) (Filer)
10-K - Teladoc Health, Inc. (0001477449) (Filer)
8-K - Teladoc Health, Inc. (0001477449) (Filer)
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today reported financial results for the three months ended December 31, 2025 ("Fourth Quarter 2025") and full year ended December 31, 2025 ("Full Year 2025"). Unless otherwise noted, percentage and other changes are relative to the three months ended December 31, 2024 ("Fourth Quarter 2024") and full year ended December 31, 2024 ("Full Year 2024"). Highlights Fourth Quarter 2025 revenue of $642.3 million, flat year-over-year, and Full Year 2025 revenue of $2,530.0 million, down 2% year-over-yearFourth Quarter 2025 net loss of $25.1 million, or $0.14 per share, and Full Year 2
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced the appointment of Michael Smith to its board of directors. With more than three decades of leadership experience in financial management and strategic transformation, Mr. Smith brings a deep understanding of long-term business sustainability within highly regulated, global markets. He joins the board following the previously announced retirements of Eric Evans and Thomas McKinley and will serve on the board's audit and nominating and corporate governance committees. "Michael's experience leading enterprise transformations makes him a strong addition to the Board," sa
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE:TDOC), the global leader in virtual care, announced that it will release fourth quarter 2025 results on Wednesday, February 25, 2026, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day. Conference Call Details The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 330912. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/events/global-numbers?confId=95347. A live audio webcast will also be available online at https:/
4 - Teladoc Health, Inc. (0001477449) (Issuer)
3 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- MarketNewsUpdates News Commentary A recent report from ResearchAndMarkets said that the U.S. augmented reality and virtual reality in healthcare market size which was estimated at USD 1.03 billion in 2024 is projected to grow at a CAGR of 15.4% from 2025 to 2030. It said that advancements in healthcare IT infrastructure and increased venture capital investment, fueled by numerous start-ups and government programs such as NIH and FDA initiatives, support AR/VR research. In addition, the declining cost of head-mounted devices, rising demand from telemedicine, chronic disease care, and minimally invasive surgery, and integration with AI and 5G tech
Jason Gorevic to depart the company, effective immediatelyCFO Mala Murthy appointed acting chief executiveTeladoc Health reaffirms guidance PURCHASE, NY, April 05, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today announced that Jason Gorevic is departing the company, effective immediately. The Board of Directors has appointed Mala Murthy acting Chief Executive Officer while it searches for Mr. Gorevic's permanent successor. Ms. Murthy is a seasoned industry leader who has served as the Company's Chief Financial Officer since 2019, and she will continue serving in this role during this transition period. The Board has ret
PURCHASE, NY, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today appointed Eric Evans to the company's board of directors. Mr. Evans, currently chief executive officer and director of Brentwood, TN-based Surgery Partners, Inc. (NASDAQ:SGRY), is a recognized healthcare and hospital executive with significant experience leading complex organizations operating at the intersection of care and technology. Mr. Evans joins the board following the retirement of Senator William Frist, M.D. earlier this year, and will serve on the board's compensation committee. David B. Snow, Jr., non-executive Chairman of the company's board,
SC 13G - Teladoc Health, Inc. (0001477449) (Subject)
SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)
SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today reported financial results for the three months ended December 31, 2025 ("Fourth Quarter 2025") and full year ended December 31, 2025 ("Full Year 2025"). Unless otherwise noted, percentage and other changes are relative to the three months ended December 31, 2024 ("Fourth Quarter 2024") and full year ended December 31, 2024 ("Full Year 2024"). Highlights Fourth Quarter 2025 revenue of $642.3 million, flat year-over-year, and Full Year 2025 revenue of $2,530.0 million, down 2% year-over-yearFourth Quarter 2025 net loss of $25.1 million, or $0.14 per share, and Full Year 2
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced the appointment of Michael Smith to its board of directors. With more than three decades of leadership experience in financial management and strategic transformation, Mr. Smith brings a deep understanding of long-term business sustainability within highly regulated, global markets. He joins the board following the previously announced retirements of Eric Evans and Thomas McKinley and will serve on the board's audit and nominating and corporate governance committees. "Michael's experience leading enterprise transformations makes him a strong addition to the Board," sa
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE:TDOC), the global leader in virtual care, announced that it will release fourth quarter 2025 results on Wednesday, February 25, 2026, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day. Conference Call Details The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 330912. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/events/global-numbers?confId=95347. A live audio webcast will also be available online at https:/